Add to ORKGIntroduction: Cetuximab, an epidermal growth factor (EGFR) inhibitor has radio sensitizing activity for locoregionally, advanced head and neck cancer (LAHNC). The drug is either used in combination with radiotherapy or in combination with other chemotherapeutic drugs.Case Presentation: A 35-year-old male patient diagnosed with cancer of tongue atloco regional stage who had previously undergone hemiglossectomy was treated with TPF (docetaxel, cisplatin and 5-fluorouracil) as induction therapy(ICT)followed by concurrent local radiation therapy (RT) and cetuximab for 6weeks.The first recurrence appeared 4 years after the surgery, which was treated with RT along with standard treatment with cetuximab for 6weeks.Second recurrence was treated wit...
International audiencePurposeTo investigate the effect of adding concurrent chemotherapy (CT) to cet...
Background: We investigated the tolerability of cetuximab plus radiotherapy in Japanese patients wit...
Abstract: The worldwide incidence of head and neck cancer exceeds half a million cases annually with...
Mohamedtaki A Tejani, Roger B Cohen, Ranee MehraDepartment of Medical Oncology, Fox Chase Cancer Cen...
Background: The use of cetuximab in combination with platinum (P) plus 5-fluorouracil (F) has previo...
Objective: To retrospectively study the clinical characteristics and treatment outcomes in patients ...
Background: Cetuximab is effective in platinum-resistant recurrent or metastatic squamous-cell carci...
A combination of cetuximab and sorafenib in patients with recurrent and/or metastatic (R/M) head and...
Background: Cetuximab and docetaxel have single-agent activity in squamous cell carcinoma of the hea...
PurposeTreatment with cisplatin or cetuximab combined with radiotherapy each yield superior survival...
Cetuximab remains to date the only targeted therapy approved for the treatment of head and neck squa...
Cetuximab remains to date the only targeted therapy approved for the treatment of head and neck squa...
Background The purpose of this study was to assess the efficacy, safety, and pharmacokinetics of cis...
Background: Induction chemotherapy (IC) is a treatment option for locally advanced squamous cell car...
Cetuximab remains to date the only targeted therapy approved for the treatment of head and neck squa...
International audiencePurposeTo investigate the effect of adding concurrent chemotherapy (CT) to cet...
Background: We investigated the tolerability of cetuximab plus radiotherapy in Japanese patients wit...
Abstract: The worldwide incidence of head and neck cancer exceeds half a million cases annually with...
Mohamedtaki A Tejani, Roger B Cohen, Ranee MehraDepartment of Medical Oncology, Fox Chase Cancer Cen...
Background: The use of cetuximab in combination with platinum (P) plus 5-fluorouracil (F) has previo...
Objective: To retrospectively study the clinical characteristics and treatment outcomes in patients ...
Background: Cetuximab is effective in platinum-resistant recurrent or metastatic squamous-cell carci...
A combination of cetuximab and sorafenib in patients with recurrent and/or metastatic (R/M) head and...
Background: Cetuximab and docetaxel have single-agent activity in squamous cell carcinoma of the hea...
PurposeTreatment with cisplatin or cetuximab combined with radiotherapy each yield superior survival...
Cetuximab remains to date the only targeted therapy approved for the treatment of head and neck squa...
Cetuximab remains to date the only targeted therapy approved for the treatment of head and neck squa...
Background The purpose of this study was to assess the efficacy, safety, and pharmacokinetics of cis...
Background: Induction chemotherapy (IC) is a treatment option for locally advanced squamous cell car...
Cetuximab remains to date the only targeted therapy approved for the treatment of head and neck squa...
International audiencePurposeTo investigate the effect of adding concurrent chemotherapy (CT) to cet...
Background: We investigated the tolerability of cetuximab plus radiotherapy in Japanese patients wit...
Abstract: The worldwide incidence of head and neck cancer exceeds half a million cases annually with...